IMV: Immunotherapy for Cancer Treatment

Developing a new class of cancer immunotherapies

IMV Inc. is a clinical-stage biopharmaceutical company. They’re developing a new class of cancer immunotherapies and vaccines to treat infectious diseases such as COVID-19. Further, the company is deeply committed to making immunotherapy and vaccines more effective, more broadly applicable, and more widely available to patients.

“We are developing a new type of treatment for cancer. It’s based on immunotherapy. It is using your your own immune system to cure cancer,” says CEO Frederic Ors.

 DPX Platform

The DPX platform uses a versatile technology that generates a targeted, robust and sustained immune response. Moreover, thanks to its unique “no release” delivery system, their proprietary DPX delivery platform can be formulated with peptide antigens to induce a specific, robust, and sustained immune response. Additionally, IMV is leveraging this mechanism of action to generate “first-in-class” T cell therapies for patients facing cancer. In the context of infectious diseases, the DPX platform can also be formulated with B cell epitopes to target virus’ specific regions like spike proteins of the SARS-CoV2.

For more information on IMV Inc. (TSX: IMV, Nasdaq: IMV) please fill out the form below.

Request Investor Info